# Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

Source: https://onco.cc/trials/nct06943755/  
OnCo record `nct06943755` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial testing Zanzalintinib in neuroendocrine tumours, now recruiting.

## Summary

Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumours is a phase 2/3 interventional study registered as NCT06943755, led by Exelixis, and recruiting on the registry. Official title: A Phase 2/3, Multicenter, Randomised Open-Label Study of Zanzalintinib vs Everolimus in Participants With Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine Tumours. Planned enrolment is 440 participants (estimated). The study started in 2025-07-21 and primary completion is expected in 2029-06-30. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-11
- Also known as: STELLAR-311
- Tags: ctgov-ingest
- Registry id: NCT06943755
- Phase: 2/3
- Setting: A Phase 2/3, Multicenter, Randomized Open-Label Study of Zanzalintinib vs Everolimus in Participants With Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine Tumors
- Sponsor: Exelixis
- Enrolled: 440

## Sources

- ClinicalTrials.gov NCT06943755: https://clinicaltrials.gov/study/NCT06943755

## Connected records

- cancers: [Lung neuroendocrine tumours (typical and atypical carcinoid)](https://onco.cc/cancers/lung-net/), [Neuroendocrine tumours](https://onco.cc/cancers/neuroendocrine/), [Pancreatic neuroendocrine tumours](https://onco.cc/cancers/pancreatic-net/), [Small intestinal neuroendocrine tumours](https://onco.cc/cancers/small-intestinal-net/)
- drugs: [Zanzalintinib](https://onco.cc/drugs/zanzalintinib/)
- companies: [Exelixis](https://onco.cc/companies/exelixis/)

---
JSON: https://onco.cc/api/v1/entities/nct06943755.json